Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonafexor (EYP001a) in NASH (LIVIFY)
NCT03812029Phase 2Completed
- Sponsor
- ENYO Pharma
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of vonafexor in Nonalcoholic steatohepatitis (NASH) (7 arms), sponsored by ENYO Pharma. Primary endpoint: Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by MRI-PDFF at 12 weeks. Started Jan 2019; status: completed.
02
Drugs
vonafexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03812029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812029.